Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Forecast 2026–2030 Highlighting Expansion Across Industries
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Growth In Market Value Is Expected For The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Between 2026 And 2030?
The programmed death (pd)-1 non-small cell lung cancer market size has experienced significant expansion in recent years. This market is anticipated to increase from $27.5 billion in 2025 to $29.92 billion in 2026, registering a compound annual growth rate (CAGR) of 8.8%. Historically, the growth can be ascribed to elements such as limited pd-1 inhibitors approved for nsclc, the rising incidence of lung cancer, heightened physician awareness concerning immune checkpoint therapies, the reliance on chemotherapy as standard care, and the initial clinical trial successes of pembrolizumab and nivolumab.
The programmed death (pd)-1 non-small cell lung cancer market size is anticipated to experience robust growth in the coming years. It is projected to expand to $41.45 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.5%. This growth during the forecast period is attributable to the development of novel combination therapies, the broadening of biomarker-driven personalized treatments, increased adoption of mRNA vaccine-based therapies, rising investment in immuno-oncology research, and greater government and private funding for cancer immunotherapy. Prominent trends expected in this period include an increased uptake of pd-1 monotherapy for nsclc, an expansion of combination therapies involving chemotherapy, ctla-4 inhibitors, and vegf inhibitors, increased investment in targeted therapy and mrna vaccine research, an extension of first-line and second-line treatment options, and the integration of personalized medicine along with biomarker testing into treatment planning.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25888&type=smp
Which Important Drivers Are Guiding The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Growth?
The increasing integration of personalized treatments is anticipated to drive forward the growth of the programmed death (PD)-1 non-small cell lung cancer market. These treatments are medical approaches specifically tailored to an individual’s genetic profile, lifestyle, and distinct disease characteristics to achieve more effective and targeted outcomes. The escalating demand for personalized treatments stems from the wider availability of genomic profiling and biomarker testing. These technologies are instrumental in identifying specific mutations and biological markers, thereby enabling clinicians to select therapies that are more likely to be efficacious for each patient. Personalized treatments benefit programmed death (PD)-1 non-small cell lung cancer (NSCLC) by customizing therapies based on a patient’s genetic profile, tumor attributes, and immune response. For instance, in February 2024, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023, significantly more than the 6 approved in the year 2022, according to the Personalized Medicine Coalition, a US-based non-profit organization. Thus, the rising adoption of personalized treatments is a primary factor fueling the expansion of the programmed death (PD)-1 non-small cell lung cancer market.
Which Segment Types Are Examined In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Segment Study?
The programmed death (pd)-1 non-small cell lung cancer market covered in this report is segmented –
1) By Drug Type: Monotherapy, Combination Therapy
2) By Line of Therapy: First-line Treatment, Second-line And Beyond
3) By End User: Hospitals, Specialty Cancer Centers, Academic And Research Institutes, Other End Users
Subsegments:
1) By Monotherapy: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Toripalimab, Tislelizumab, Camrelizumab, Dostarlimab, Other Monotherapy Drug Types
2) By Combination Therapy: Programmed Death (PD)-1 Inhibitor And Chemotherapy, Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor, Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor, Programmed Death (PD)-1 Inhibitor And Targeted Therapy, Programmed Death (PD)-1 Inhibitor And Radiation Therapy, Triple Combination Therapy, Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine, Other Combination Drug Types
Which Trends Are Contributing To Changes In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?
Leading firms within the programmed death (PD)-1 non-small cell lung cancer market are prioritizing clinical investigations into novel treatments, including monotherapy, aimed at enhancing patient results. Monotherapy involves employing a singular medication or therapeutic method to address an illness or ailment. As an illustration, Akeso, Inc., a biopharmaceutical firm based in China, revealed favorable findings in March 2025 from its Phase III HARMONi-2 trial, which assessed Ivonescimab (AK112) alongside chemotherapy for the initial treatment of advanced non-small cell lung cancer (NSCLC). This investigation achieved its main objective by considerably prolonging progression-free survival in contrast to pembrolizumab, underscoring the therapeutic promise of the dual-targeted bispecific antibody.
Which Players Are Part Of The Competitive Landscape Of The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?
Major companies operating in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., Shanghai Henlius Biotech Inc.
Get The Full Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report:
Which Region Leads The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market In Overall Market Size?
North America was the largest region in the programmed death (PD)-1 non-small cell lung cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the programmed death (pd)-1 non-small cell lung cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market 2026, By The Business Research Company
Pd 1 And Pdl1 Inhibitors Or Immune Checkpoint Inhibitors Market Report 2026
Non Small Cell Lung Cancer Nsclc Market Report 2026
Small Cell Lung Cancer Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
